MANGANESE CHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for manganese chloride and what is the scope of patent protection?
Manganese chloride
is the generic ingredient in three branded drugs marketed by Fresenius Kabi Usa, Hospira, and Bracco, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.Two suppliers are listed for this compound.
Summary for MANGANESE CHLORIDE
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 28 |
| Clinical Trials: | 6 |
| Drug Prices: | Drug price trends for MANGANESE CHLORIDE |
| What excipients (inactive ingredients) are in MANGANESE CHLORIDE? | MANGANESE CHLORIDE excipients list |
| DailyMed Link: | MANGANESE CHLORIDE at DailyMed |
Recent Clinical Trials for MANGANESE CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ascelia Pharma AB | Phase 3 |
| Chinese PLA General Hospital | Phase 1/Phase 2 |
| Chinese PLA General Hospital | Phase 1 |
Pharmacology for MANGANESE CHLORIDE
| Drug Class | Paramagnetic Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
US Patents and Regulatory Information for MANGANESE CHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | MANGANESE CHLORIDE | manganese chloride | INJECTABLE;INJECTION | 217583-001 | Jul 7, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Bracco | LUMENHANCE | manganese chloride tetrahydrate | FOR SOLUTION;ORAL | 020686-001 | Dec 19, 1997 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hospira | MANGANESE CHLORIDE IN PLASTIC CONTAINER | manganese chloride | INJECTABLE;INJECTION | 018962-001 | Jun 26, 1986 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch